Akihisa Sakamoto

TL;DR: This work developed ERY974, a whole humanized immunoglobulin G–structured TRAB harboring a common light chain, which bispecifically binds to GPC3 and CD3 and induced a robust antitumor efficacy even against tumors with nonimmunogenic features, which are difficult to treat by inhibiting immune checkpoints such as PD-1 and CTLA-4.

TL;DR: A long-term primate model of acquired hemophilia A is newly established by multiple IV injections of an anti-primate FVIII neutralizing antibody engineered in mouse-monkey chimeric form to reduce its antigenicity.

TL;DR: SKY59 is a promising new anti-C5 agent for patients with PNH and other complement-mediated disorders and neutralizing effect on C5 variant p.Arg885His is shown, while eculizumab does not inhibit complement activity in patients carrying this mutation.

TL;DR: By replacing the antigen-binding domain, the present inventors discovered novel polypeptide complexes that retain BiTE's strong anti-tumor activity and excellent safety properties, as well as have long half-life in blood and can damage various different target cells as discussed by the authors.

TL;DR: A novel anti-CD137 switch antibody is generated, STA551, which exerts agonistic activity only in the presence of exATP, which demonstrates potent and broad anti-tumor efficacy against all mouse and human tumors tested and a wide therapeutic window without systemic immune activation in mice.